Natural antibodies as rheostats for susceptibility to chronic diseases in the aged

Frontiers in Immunology

Volumn 7, Issue APR, 2016, Pages

  Rothstein, Thomas L ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

B 1 cells; Human B cells; Natural antibody

Indexed keywords

AMYLOID PROTEIN; ANTIBODY; BREAKPOINT CLUSTER REGION PROTEIN; CD27 ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M ANTIBODY; LUNG CANCER; METHYLGLYOXAL; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; N ACETYLNEURAMINIC ACID DERIVATIVE; OXIDIZED LOW DENSITY LIPOPROTEIN; RACOTUMOMAB; TAU PROTEIN; UNCLASSIFIED DRUG;

AGE; AGED; ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; B1 CELL; CAROTID ARTERY DISEASE; CELL VIABILITY; CHRONIC DISEASE; DISEASE PREDISPOSITION; HOMEOSTASIS; HUMAN; HYPOTHESIS; IMMUNOCOMPETENT CELL; NERVE DEGENERATION; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN PHOSPHORYLATION; REPRODUCIBILITY; SIGNAL TRANSDUCTION;

EID: 84966712951     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00127     Document Type: Article

References (106)

1. Ochsenbein AF, Fehr T, Lutz C, Suter M, Brombacher F, Hengartner H, et al. Control of early viral and bacterial distribution and disease by natural antibodies. Science (1999) 286:2156-9. doi: 10.1126/science.286.5447.2156
2. Baumgarth N, Herman OC, Jager GC, Brown LE, Herzenberg LA, Chen J. B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. J Exp Med (2000) 192:271-80. doi:10.1084/jem.192.2.271
3. Boes M, Prodeus AP, Schmidt T, Carroll MC, Chen J. A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J Exp Med (1998) 188:2381-6. doi:10.1084/jem.188.12.2381
4. Briles DE, Nahm M, Schroer K, Davie J, Baker P, Kearney J, et al. Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 Streptococcus pneumoniae. J Exp Med (1981) 153:694-705. doi:10.1084/jem.153.3.694
5. Haas KM, Poe JC, Steeber DA, Tedder TF. B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity (2005) 23:7-18. doi:10.1016/j.immuni.2005.04.011
6. Baccala R, Quang TV, Gilbert M, Ternynck T, Avrameas S. Two murine natural polyreactive autoantibodies are encoded by nonmutated germ-line genes. Proc Natl Acad Sci U S A (1989) 86:4624-8. doi:10.1073/pnas.86.12.4624
7. Hartman AB, Mallett CP, Srinivasappa J, Prabhakar BS, Notkins AL, Smith-Gill SJ. Organ reactive autoantibodies from non-immunized adult BALB/c mice are polyreactive and express non-biased VH gene usage. Mol Immunol (1989) 26:359-70. doi:10.1016/0161-5890(89)90125-9
8. Lalor PA, Morahan G. The peritoneal Ly-1 (CD5) B cell repertoire is unique among murine B cell repertoires. Eur J Immunol (1990) 20:485-92. doi:10.1002/eji.1830200305
9. Klinman DM, Holmes KL. Differences in the repertoire expressed by peritoneal and splenic Ly-1 (CD5)+ B cells. J Immunol (1990) 144:4520-5
10. Briles DE, Forman C, Hudak S, Claflin JL. Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. J Exp Med (1982) 156:1177-85. doi:10.1084/jem.156.4.1177
11. Shaw PX, Horkko S, Chang MK, Curtiss LK, Palinski W, Silverman GJ, et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest (2000) 105:1731-40. doi:10.1172/JCI8472
12. Tsimikas S, Brilakis ES, Lennon RJ, Miller ER, Witztum JL, McConnell JP, et al. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res (2007) 48:425-33. doi:10.1194/jlr.M600361-JLR200
13. Soto Y, Conde H, Aroche R, Brito V, Luaces P, Nasiff A, et al. Autoantibodies to oxidized low density lipoprotein in relation with coronary artery disease. Hum Antibodies (2009) 18:109-17. doi:10.3233/HAB-2009-0202
14. Kyaw T, Tay C, Krishnamurthi S, Kanellakis P, Agrotis A, Tipping P, et al. B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. Circ Res (2011) 109:830-40. doi:10.1161/CIRCRESAHA.111.248542
15. Hardy RR, Carmack CE, Shinton SA, Riblet RJ, Hayakawa K. A single VH gene is utilized predominantly in anti-BrMRBC hybridomas derived from purified Ly-1 B cells. Definition of the VH11 family. J Immunol (1989) 142:3643-51
16. Pennell CA, Sheehan KM, Brodeur PH, Clarke SH. Organization and expression of VH gene families preferentially expressed by Ly-1+ (CD5) B cells. Eur J Immunol (1989) 19:2115-21. doi:10.1002/eji.1830191122
17. Chen Y, Park YB, Patel E, Silverman GJ. IgM antibodies to apoptosis-associated determinants recruit C1q and enhance dendritic cell phagocytosis of apoptotic cells. J Immunol (2009) 182:6031-43. doi:10.4049/jimmunol.0804191
18. Rothstein TL, Griffin DO, Holodick NE, Quach TD, Kaku H. Human B-1 cells take the stage. Ann N Y Acad Sci (2013) 1285:97-114. doi:10.1111/nyas.12137
19. Montecino-Rodriguez E, Leathers H, Dorshkind K. Identification of a B-1 B cell-specified progenitor. Nat Immunol (2006) 7:293-301. doi:10.1038/ni1301
20. Ghosn EE, Waters J, Phillips M, Yamamoto R, Long BR, Yang Y, et al. Fetal hematopoietic stem cell transplantation fails to fully regenerate the B-lymphocyte compartment. Stem Cell Rep (2015) 6:137-49. doi:10.1016/j.stemcr.2015.10.011
21. Griffin DO, Holodick NE, Rothstein TL. Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+CD27+CD43+CD70. J Exp Med (2011) 208:67-80. doi:10.1084/jem.201014992084c
22. Griffin DO, Rothstein TL. Human B1 cell frequency: isolation and analysis of human B1 cells. Front Immunol (2012) 3:122. doi:10.3389/fimmu.2012.00122
23. Quach TD, Rodriguez-Zhurbenko N, Hopkins TJ, Guo X, Hernandez AM, Li W, et al. Distinctions among circulating antibody-secreting cell populations, including B-1 cells, in human adult peripheral blood. J Immunol (2016) 196(3):1060-9. doi:10.4049/jimmunol.1501843
24. Griffin DO, Holodick NE, Rothstein TL. Human B1 cells are CD3-: a reply to "A human equivalent of mouse B-1 cells?" and "The nature of circulating CD27+CD43+ B cells." J Exp Med (2011) 208:2566-9. doi:10.1084/jem.20111761
25. Kraljevic K, Wong S, Fulcher DA. Circulating phenotypic B-1 cells are decreased in common variable immunodeficiency and correlate with immunoglobulin M levels. Clin Exp Immunol (2013) 171:278-82. doi:10.1111/cei.12008
26. Suchanek O, Sadler R, Bateman EA, Patel SY, Ferry BL. Immunophenotyping of putative human B1 B cells in healthy controls and common variable immunodeficiency (CVID) patients. Clin Exp Immunol (2012) 170:333-41. doi:10.1111/j.1365-2249.2012.04656.x
27. Li W, Batliwalla F, Rothstein TL. Human B-1 cells are not preplasmablasts: analysis of microarray data and other issues. Blood (2013) 122:3691-3. doi:10.1182/blood-2013-08-520031
28. Verbinnen B, Covens K, Moens L, Meyts I, Bossuyt X. Human CD20+CD43+CD27+CD5- B cells generate antibodies to capsular polysaccharides of Streptococcus pneumoniae. J Allergy Clin Immunol (2012) 130:272-5. doi:10.1016/j.jaci.2012.04.040
29. Leggat DJ, Khaskhely NM, Iyer AS, Mosakowski J, Thompson RS, Weinandy JD, et al. Pneumococcal polysaccharide vaccination induces polysaccharide-specific B cells in adult peripheral blood expressing CD19CD20CD3CD70CD27IgMCD43CD5. Vaccine (2013) 31:4632-40. doi:10.1016/j.vaccine.2013.07.030
30. Torring C, Petersen CC, Bjerg L, Kofod-Olsen E, Petersen T, Hollsberg P. The B1-cell subpopulation is diminished in patients with relapsing-remitting multiple sclerosis. J Neuroimmunol (2013) 262:92-9. doi:10.1016/j.jneuroim.2013.06.002
31. Moins-Teisserenc H, Busson M, Herda A, Apete S, Peffault de Latour R, Robin M, et al. CD19+CD5+ B cells and B1-like cells following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2013) 19:988-91. doi:10.1016/j.bbmt.2013.03.006
32. Gu H, Forster I, Rajewsky K. Sequence homologies, N sequence insertion and JH gene utilization in VHDJH joining: implications for the joining mechanism and the ontogenetic timing of Ly1 B cell and B-CLL progenitor generation. EMBO J (1990) 9:2133-40
33. Forster I, Gu H, Rajewsky K. Germline antibody V regions as determinants of clonal persistence and malignant growth in the B cell compartment. EMBO J (1988) 7:3693-703
34. Pennell CA, Mercolino TJ, Grdina TA, Arnold LW, Haughton G, Clarke SH. Biased immunoglobulin variable region gene expression by Ly-1 B cells due to clonal selection. Eur J Immunol (1989) 19:1289-95. doi:10.1002/eji.1830190721
35. Payne KJ, Crooks GM. Immune-cell lineage commitment: translation from mice to humans. Immunity (2007) 26:674-7. doi:10.1016/j.immuni.2007.05.011
36. Binder CJ. Natural IgM antibodies against oxidation-specific epitopes. J Clin Immunol (2010) 30(Suppl 1):S56-60. doi:10.1007/s10875-010-9396-3
37. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med (2005) 352:1685-95. doi:10.1056/NEJMra043430
38. McLeod O, Silveira A, Fredrikson GN, Gertow K, Baldassarre D, Veglia F, et al. Plasma autoantibodies against apolipoprotein B-100 peptide 210 in subclinical atherosclerosis. Atherosclerosis (2014) 232:242-8. doi:10.1016/j.atherosclerosis.2013.11.041
39. Engelbertsen D, Anand DV, Fredrikson GN, Hopkins D, Corder R, Shah PK, et al. High levels of IgM against methylglyoxal-modified apolipoprotein B100 are associated with less coronary artery calcification in patients with type 2 diabetes. J Intern Med (2012) 271:82-9. doi:10.1111/j.1365-2796.2011.02411.x
40. Fredrikson GN, Hedblad B, Berglund G, Alm R, Nilsson JA, Schiopu A, et al. Association between IgM against an aldehyde-modified peptide in apolipoprotein B-100 and progression of carotid disease. Stroke (2007) 38:1495-500. doi:10.1161/STROKEAHA.106.474577
41. Rodriguez-Zhurbenko N, Martinez D, Blanco R, Rondon T, Grinan T, Hernandez AM. Human antibodies reactive to NeuGcGM3 ganglioside have cytotoxic anti-tumor properties. Eur J Immunol (2013) 43:826-37. doi:10.1002/eji.201242693
42. Springer SA, Diaz SL, Gagneux P. Parallel evolution of a self-signal: humans and new world monkeys independently lost the cell surface sugar Neu5Gc. Immunogenetics (2014) 66:671-4. doi:10.1007/s00251-014-0795-0
43. Chou HH, Hayakawa T, Diaz S, Krings M, Indriati E, Leakey M, et al. Inactivation of CMP-N-acetylneuraminic acid hydroxylase occurred prior to brain expansion during human evolution. Proc Natl Acad Sci U S A (2002) 99:11736-41. doi:10.1073/pnas.182257399
44. Rodriguez-Zhurbenko N, Rabade-Chediak M, Martinez D, Grinan T, Hernandez AM. Anti-NeuGcGM3 reactivity: a possible role of natural antibodies and B-1 cells in tumor immunosurveillance. Ann N Y Acad Sci (2015) 1362:224-38. doi:10.1111/nyas.12827
45. Szabo P, Relkin N, Weksler ME. Natural human antibodies to amyloid beta peptide. Autoimmun Rev (2008) 7:415-20. doi:10.1016/j.autrev.2008.03.007
46. Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, et al. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 106:12145-50. doi:10.1073/pnas.0904866106
47. Rosenmann H, Meiner Z, Geylis V, Abramsky O, Steinitz M. Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects. Neurosci Lett (2006) 410:90-3. doi:10.1016/j.neulet.2006.01.072
48. Terryberry JW, Thor G, Peter JB. Autoantibodies in neurodegenerative diseases: antigen-specific frequencies and intrathecal analysis. Neurobiol Aging (1998) 19:205-16. doi:10.1016/S0197-4580(98)00049-9
49. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet (2011) 377:1019-31. doi:10.1016/S0140-6736(10)61349-9
50. Tsiantoulas D, Sage AP, Mallat Z, Binder CJ. Targeting B cells in atherosclerosis: closing the gap from bench to bedside. Arterioscler Thromb Vasc Biol (2015) 35:296-302. doi:10.1161/ATVBAHA.114.303569
51. Morris-Rosenfeld S, Lipinski MJ, McNamara CA. Understanding the role of B cells in atherosclerosis: potential clinical implications. Expert Rev Clin Immunol (2014) 10:77-89. doi:10.1586/1744666X.2014.857602
52. Mayr M, Kiechl S, Tsimikas S, Miller E, Sheldon J, Willeit J, et al. Oxidized low-density lipoprotein autoantibodies, chronic infections, and carotid atherosclerosis in a population-based study. J Am Coll Cardiol (2006) 47:2436-43. doi:10.1016/j.jacc.2006.03.024
53. Karvonen J, Paivansalo M, Kesaniemi YA, Horkko S. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation (2003) 108:2107-12. doi:10.1161/01.CIR.0000092891.55157.A7
54. Su J, Georgiades A, Wu R, Thulin T, de Faire U, Frostegard J. Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis (2006) 188:160-6. doi:10.1016/j.atherosclerosis.2005.10.017
55. Bui MN, Sack MN, Moutsatsos G, Lu DY, Katz P, McCown R, et al. Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis. Am Heart J (1996) 131:663-7. doi:10.1016/S0002-8703(96)90268-9
56. Inoue T, Uchida T, Kamishirado H, Takayanagi K, Hayashi T, Morooka S. Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease. J Am Coll Cardiol (2001) 37:775-9. doi:10.1016/S0735-1097(00)01199-2
57. Lehtimaki T, Lehtinen S, Solakivi T, Nikkila M, Jaakkola O, Jokela H, et al. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol (1999) 19:23-7. doi:10.1161/01.ATV.19.1.23
58. Maiolino G, Pedon L, Cesari M, Frigo AC, Barisa M, Rossitto G, et al. Antibodies to malondialdehyde oxidized low-density lipoproteins predict long term cardiovascular mortality in high risk patients. Int J Cardiol (2013) 168:484-9. doi:10.1016/j.ijcard.2012.09.165
59. Puurunen M, Manttari M, Manninen V, Tenkanen L, Alfthan G, Ehnholm C, et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med (1994) 154:2605-9. doi:10.1001/archinte.1994.00420220105012
60. Inoue T, Uchida T, Kamishirado H, Takayanagi K, Morooka S. Antibody against oxidized low density lipoprotein may predict progression or regression of atherosclerotic coronary artery disease. J Am Coll Cardiol (2001) 37:1871-6. doi:10.1016/S0735-1097(00)01199-2
61. Boullier A, Hamon M, Walters-Laporte E, Martin-Nizart F, Mackereel R, Fruchart JC, et al. Detection of autoantibodies against oxidized low-density lipoproteins and of IgG-bound low density lipoproteins in patients with coronary artery disease. Clin Chim Acta (1995) 238:1-10. doi:10.1016/0009-8981(95)06054-H
62. Uusitupa MI, Niskanen L, Luoma J, Vilja P, Mercuri M, Rauramaa R, et al. Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol (1996) 16:1236-42. doi:10.1161/01.ATV.16.10.1236
63. van de Vijver LP, Steyger R, van Poppel G, Boer JM, Kruijssen DA, Seidell JC, et al. Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls. Atherosclerosis (1996) 122:245-53. doi:10.1016/0021-9150(95)05759-5
64. Rossi GP, Cesari M, De Toni R, Zanchetta M, Maiolino G, Pedon L, et al. Antibodies to oxidized low-density lipoproteins and angiographically assessed coronary artery disease in white patients. Circulation (2003) 108:2467-72. doi:10.1161/01.CIR.0000097122.19430.48
65. Horkko S, Bird DA, Miller E, Itabe H, Leitinger N, Subbanagounder G, et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest (1999) 103:117-28. doi:10.1172/JCI4533
66. Chang MK, Bergmark C, Laurila A, Horkko S, Han KH, Friedman P, et al. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. Proc Natl Acad Sci U S A (1999) 96:6353-8. doi:10.1073/pnas.96.11.6353
67. Engelbertsen D, Vallejo J, Quach TD, Fredrikson GN, Alm R, Hedblad B, et al. Low levels of IgM antibodies against an advanced glycation endproduct-modified apolipoprotein B100 peptide predict cardiovascular events in nondiabetic subjects. J Immunol (2015) 195:3020-5. doi:10.4049/jimmunol.1402869
68. Hernandez AM, Rodriguez N, Gonzalez JE, Reyes E, Rondon T, Grinan T, et al. Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism. J Immunol (2011) 186:3735-44. doi:10.4049/jimmunol.1000609
69. Hernandez AM, Toledo D, Martinez D, Grinan T, Brito V, Macias A, et al. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J Immunol (2008) 181:6625-34. doi:10.4049/jimmunol.181.9.6625
70. Vazquez AM, Hernandez AM, Macias A, Montero E, Gomez DE, Alonso DF, et al. Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides-preclinical and clinical data. Front Oncol (2012) 2:150. doi:10.3389/fonc.2012.00150
71. Vazquez AM, Rodreguez-Zhurbenko N, Lopez AM. Anti-ganglioside anti-idiotypic vaccination: more than molecular mimicry. Front Oncol (2012) 2:170. doi:10.3389/fonc.2012.00170
72. Alfonso S, Valdes-Zayas A, Santiesteban ER, Flores YI, Areces F, Hernandez M, et al. A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res (2014) 20:3660-71. doi:10.1158/1078-0432.CCR-13-1674
73. Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol (2002) 37:943-8. doi:10.1016/S0531-5565(02)00029-3
74. Du Y, Dodel R, Hampel H, Buerger K, Lin S, Eastwood B, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology (2001) 57:801-5. doi:10.1212/WNL.57.5.801
75. Jianping L, Zhibing Y, Wei Q, Zhikai C, Jie X, Jinbiao L. Low avidity and level of serum anti-Abeta antibodies in Alzheimer disease. Alzheimer Dis Assoc Disord (2006) 20:127-32. doi:10.1097/00002093-200607000-00001
76. Dodel R, Balakrishnan K, Keyvani K, Deuster O, Neff F, Andrei-Selmer LC, et al. Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease. J Neurosci (2011) 31:5847-54. doi:10.1523/JNEUROSCI.4401-10.2011
77. Congdon EE, Gu J, Sait HB, Sigurdsson EM. Antibody uptake into neurons occurs primarily via clathrin-dependent Fcgamma receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem (2013) 288:35452-65. doi:10.1074/jbc.M113.491001
78. Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, et al. Passive immunization with anti-tau antibodies in two transgenic models: reduction of tau pathology and delay of disease progression. J Biol Chem (2011) 286:34457-67. doi:10.1074/jbc.M111.229633
79. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem (2011) 118:658-67. doi:10.1111/j.1471-4159.2011.07337.x
80. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med (2000) 6:916-9. doi:10.1038/78682
81. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 98:8850-5. doi:10.1073/pnas.151261398
82. Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, et al. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol (2010) 33:67-73. doi:10.1097/WNF.0b013e3181cb577a
83. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 370:311-21. doi:10.1056/NEJMoa1312889
84. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 370:322-33. doi:10.1056/NEJMoa1304839
85. Anand K, Sabbagh M. Early investigational drugs targeting tau protein for the treatment of Alzheimer's disease. Expert Opin Investig Drugs (2015) 24:1355-60. doi:10.1517/13543784.2015.1075002
86. Caraux A, Klein B, Paiva B, Bret C, Schmitz A, Fuhler GM, et al. Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells. Haematologica (2010) 95:1016-20. doi:10.3324/haematol.2009.018689
87. Chong Y, Ikematsu H, Yamaji K, Nishimura M, Nabeshima S, Kashiwagi S, et al. CD27(+) (memory) B cell decrease and apoptosis-resistant CD27(-) (naive) B cell increase in aged humans: implications for age-related peripheral B cell developmental disturbances. Int Immunol (2005) 17:383-90. doi:10.1093/intimm/dxh218
88. Colonna-Romano G, Bulati M, Aquino A, Pellicano M, Vitello S, Lio D, et al. A double-negative (IgD-CD27-) B cell population is increased in the peripheral blood of elderly people. Mech Ageing Dev (2009) 130:681-90. doi:10.1016/j.mad.2009.08.003
89. Veneri D, Ortolani R, Franchini M, Tridente G, Pizzolo G, Vella A. Expression of CD27 and CD23 on peripheral blood B lymphocytes in humans of different ages. Blood Transfus (2009) 7:29-34. doi:10.2450/2008.0007-08
90. Holodick NE, Rothstein TL. B cells in the aging immune system: time to consider B-1 cells. Ann N Y Acad Sci (2015) 1362:176-87. doi:10.1111/nyas.12825
91. Yang Y, Wang C, Yang Q, Kantor AB, Chu H, Ghosn EE, et al. Distinct mechanisms define murine B cell lineage immunoglobulin heavy chain (IgH) repertoires. eLife (2015) 4:e09083. doi:10.7554/eLife.09083
92. Witztum JL, Lichtman AH. The influence of innate and adaptive immune responses on atherosclerosis. Annu Rev Pathol (2014) 9:73-102. doi:10.1146/annurev-pathol-020712-163936
93. Binder CJ, Horkko S, Dewan A, Chang MK, Kieu EP, Goodyear CS, et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med (2003) 9:736-43. doi:10.1038/nm876
94. Chou MY, Fogelstrand L, Hartvigsen K, Hansen LF, Woelkers D, Shaw PX, et al. Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest (2009) 119:1335-49. doi:10.1172/JCI36800
95. Wang C, Turunen SP, Kummu O, Veneskoski M, Lehtimaki J, Nissinen AE, et al. Natural antibodies of newborns recognize oxidative stress-related malondialdehyde acetaldehyde adducts on apoptotic cells and atherosclerotic plaques. Int Immunol (2013) 25:575-87. doi:10.1093/intimm/dxt022
96. Morris DL, Rothstein TL. Abnormal transcription factor induction through the surface immunoglobulin M receptor of B-1 lymphocytes. J Exp Med (1993) 177:857-61. doi:10.1084/jem.177.3.857
97. Hayakawa K, Asano M, Shinton SA, Gui M, Wen LJ, Dashoff J, et al. Positive selection of anti-thy-1 autoreactive B-1 cells and natural serum autoantibody production independent from bone marrow B cell development. J Exp Med (2003) 197:87-99. doi:10.1084/jem.20021459
98. Hardy RR. B-1 B cell development. J Immunol (2006) 177:2749-54. doi:10.4049/jimmunol.177.5.2749
99. Libbey JE, Peterson LK, Tsunoda I, Fujinami RS. Monoclonal MOG-reactive autoantibody from progressive EAE has the characteristics of a natural antibody. J Neuroimmunol (2006) 173:135-45. doi:10.1016/j.jneuroim.2005.12.010
100. Baumgarth N. The double life of a B-1 cell: self-reactivity selects for protective effector functions. Nat Rev Immunol (2011) 11:34-46. doi:10.1038/nri2901
101. Herzenberg LA. Layered evolution in the immune system: a view from history. Ann N Y Acad Sci (2015) 1362:1-5. doi:10.1111/nyas.12795
102. Martin F, Oliver AM, Kearney JF. Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity (2001) 14:617-29. doi:10.1016/S1074-7613(01)00129-7
103. Bagnara D, Squillario M, Kipling D, Mora T, Walczak AM, Da Silva L, et al. A reassessment of IgM memory subsets in humans. J Immunol (2015) 195:3716-24. doi:10.4049/jimmunol.1500753
104. Weller S, Braun MC, Tan BK, Rosenwald A, Cordier C, Conley ME, et al. Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood (2004) 104:3647-54. doi:10.1182/blood-2004-01-0346
105. Capolunghi F, Rosado MM, Sinibaldi M, Aranburu A, Carsetti R. Why do we need IgM memory B cells? Immunol Lett (2013) 152:114-20. doi:10.1016/j.imlet.2013.04.007
106. Hardy RR, Hayakawa K. Positive and negative selection of natural autoreactive B cells. Adv Exp Med Biol (2012) 750:227-38. doi:10.1007/978-1-4614-3461-0_17